Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.

Although all competitive neuromuscular blockers are designed to produce desirable pharmacological actions, they can also have adverse effects mediated by histamine or autonomic receptors. Drugs like tubocurarine and atracurium lead to histamine release into the systemic circulation. Histamine can cause a fall in blood pressure or hypotension. Pancuronium increases the heart rate and cardiac output. The release of larger doses of histamine can block autonomic ganglions, which affects cardiovascular functions, increasing the heart rate and blood pressure. Bradycardia occurs initially, followed by tachycardia. Prolonged administration of drugs like succinylcholine can result in cardiac arrhythmias and even cardiac arrest in some patients. Other patients may experience flushing, bronchospasm, and increased respiratory secretions.

Tags
Nondepolarizing Neuromuscular BlockersPharmacological ActionsMuscle Contraction InhibitionHistamine ReleaseCompetitive Neuromuscular BlockersAdverse EffectsTubocurarineAtracuriumHypotensionPancuroniumCardiac OutputBradycardiaTachycardiaSuccinylcholineCardiac Arrhythmias

Del capítulo 7:

article

Now Playing

7.4 : Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Skeletal Muscle Relaxants

299 Vistas

article

7.1 : Unión neuromuscular y bloqueo

Skeletal Muscle Relaxants

2.3K Vistas

article

7.2 : Clasificación de los relajantes del músculo esquelético

Skeletal Muscle Relaxants

2.2K Vistas

article

7.3 : Bloqueadores neuromusculares no despolarizantes (competitivos): mecanismo de acción

Skeletal Muscle Relaxants

1.1K Vistas

article

7.5 : Bloqueadores neuromusculares no despolarizantes (competitivos): farmacocinética

Skeletal Muscle Relaxants

383 Vistas

article

7.6 : Bloqueadores despolarizantes: mecanismo de acción

Skeletal Muscle Relaxants

918 Vistas

article

7.7 : Bloqueadores despolarizantes: farmacocinéticos

Skeletal Muscle Relaxants

250 Vistas

article

7.8 : Relajantes musculares de acción directa: Dantroleno y toxina botulínica

Skeletal Muscle Relaxants

565 Vistas

article

7.9 : Relajantes del músculo esquelético: efectos adversos

Skeletal Muscle Relaxants

283 Vistas

article

7.10 : Relajantes del músculo esquelético: usos terapéuticos

Skeletal Muscle Relaxants

405 Vistas

article

7.11 : Agentes espasmolíticos: clasificación química

Skeletal Muscle Relaxants

808 Vistas

article

7.12 : Relajantes musculares de acción periférica y central: una comparación

Skeletal Muscle Relaxants

2.8K Vistas

article

7.13 : Relajantes musculares de acción central: usos terapéuticos

Skeletal Muscle Relaxants

490 Vistas

JoVE Logo

Privacidad

Condiciones de uso

Políticas

Investigación

Educación

ACERCA DE JoVE

Copyright © 2025 MyJoVE Corporation. Todos los derechos reservados